SCHEMBL5364979

SCHEMBL5364979

COc1ccc(C=C2C(=O)Nc3ccc(S(=O)(=O)Nc4ccc(C(F)(F)F)cc4)cc32)cc1OC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.61
ALOX15 P16050 1/20 0.61
MAPK1 P28482 1/20 0.61
KMT2A Q03164 1/20 0.61
MOGAT2 Q3SYC2 3/20 0.55
MGAT2 Q10469 2/20 0.51
PSEN1 P49768 3/20 0.50
PSEN2 P49810 3/20 0.50
APH1B Q8WW43 3/20 0.50
NCSTN Q92542 3/20 0.50
APH1A Q96BI3 3/20 0.50
PSENEN Q9NZ42 3/20 0.50
NOX4 Q9NPH5 1/20 0.49
ERBB2 P04626 2/20 0.48
EGFR P00533 1/20 0.48
PAK1 Q13153 1/20 0.47
FLT3 P36888 2/20 0.47
GSK3B P49841 2/20 0.46
BRD4 O60885 1/20 0.46
HDAC4 P56524 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5361498 0.93 MEN1 (0.53) MEN1ALOX15MAPK1KMT2AMOGAT2
SCHEMBL7132861 0.93 MEN1 (0.54) MEN1ALOX15MAPK1KMT2AMOGAT2
SCHEMBL7133918 0.93 KMT2A (0.54) MEN1ALOX15MAPK1KMT2AMOGAT2
SCHEMBL7135582 0.92 MEN1 (0.53) MEN1ALOX15MAPK1KMT2AMOGAT2
SCHEMBL5369597 0.91 ERBB2 (0.61) MEN1ALOX15MAPK1KMT2AMOGAT2
SCHEMBL5364814 0.91 GSK3B (0.57) MEN1ALOX15MAPK1KMT2AMOGAT2
SCHEMBL5369913 0.89 MOGAT2 (0.56) MEN1ALOX15MAPK1KMT2AMOGAT2
SCHEMBL5358368 0.89 MOGAT2 (0.61) MEN1ALOX15MAPK1KMT2AMOGAT2
SCHEMBL5368257 0.88 MEN1 (0.57) MEN1ALOX15MAPK1KMT2AMOGAT2
SCHEMBL5368753 0.88 MOGAT2 (0.51) MEN1ALOX15MAPK1KMT2AMOGAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK MEN1 3855/4885ALOX15 748/4885MAPK1 424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.